Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04674189 Completed - Covid19 Clinical Trials

A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19

Start date: December 23, 2020
Phase: Phase 3
Study type: Interventional

This study aims to evaluate the safety (in all participants) and reactogenicity (in a subset of participants) of CVnCoV administered as a 2-dose schedule to adult participants 18 years of age or older. The study also aims to assess antibody responses to the receptor-binding domain (RBD) of spike (S) protein of SARS-CoV-2 after 1 and 2 doses of CVnCoV in adults 18 years of age or older included in a subset of participants.

NCT ID: NCT04673331 Completed - Cystic Fibrosis Clinical Trials

Physical Activity, Exercise Capacity and Coronavirus Phobia of Adult Cystic Fibrosis Patients During COVID-19 Pandemic

Start date: November 4, 2020
Phase:
Study type: Observational

The purpose of this study was to evaluate physical activity, exercise capacity, quality of life, cognitive status level and coronavirus phobia level of adult cystic fibrosis patients and compare with the findings of healthy subjects with teleconference during COVID-19 pandemic.

NCT ID: NCT04673318 Recruiting - Covid19 Clinical Trials

Physical Rehabilitation of COVID-19 Survivors by Heat Therapy

Start date: February 26, 2021
Phase: N/A
Study type: Interventional

Older adults and people with underlying medical conditions are at higher risk for developing serious complications related to SARS-CoV-2 resulting in prolonged sequelae. The goal of this proposal is to compare the benefits of home-based lower limb heat therapy to exercise training on cardio-metabolic function and mobility in older adults during their convalescence from hospitalization due to SARS-CoV-2.

NCT ID: NCT04673214 Completed - Covid19 Clinical Trials

Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment

Start date: December 16, 2020
Phase: Phase 3
Study type: Interventional

The present study is designed for patients with mild COVID-19 phase, to demonstrate if there is a modification in the clinical evolution greater than or equal to 25% in their symptoms, implemented in two groups of patients under an early intervention treatment, a group ( A) will receive Azithromycin / Ivermectin / Ribaroxaban / Paracetamol and another group (B) will receive Azithromycin / Ribaroxaban / Paracetamol followed for 14 days followed by video call

NCT ID: NCT04673162 Completed - Covid19 Clinical Trials

Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients

Start date: December 17, 2020
Phase: Phase 3
Study type: Interventional

This double blind, randomized study is aiming to evaluate the efficacy of three doses (1gr/day) of methylpredisolone added to standard therapy in patients, with documented COVID-19 pneumonia, requiring hospitalization but not mechanical ventilation.

NCT ID: NCT04672564 Terminated - Clinical trials for Coronavirus Disease 2019

Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

Start date: March 30, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.

NCT ID: NCT04672395 Completed - COVID-19 Clinical Trials

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

SCB-2019
Start date: March 24, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike (S)-protein subunit vaccine (SCB-2019) for the prevention of SARS-CoV-2-mediated COVID-19 in Participants Aged 12 Years and Older.

NCT ID: NCT04672291 Completed - COVID - 19 Clinical Trials

Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults

Start date: July 21, 2021
Phase: Phase 1
Study type: Interventional

This is a randomized (4:1) Phase 1 b safety trial in adults who have completed their full COVID-19 vaccination schedule at least 30 days prior to study entry.

NCT ID: NCT04671017 Completed - Clinical trials for SARS-CoV-2 Virus Infection

Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS-CoV-2 Virus Vaccine Candidate Against Covid-19 in Healthy Subjects

Start date: December 16, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A multicenter, 3-arm randomized dose finding study in the UK to evaluate safety, tolerability and immunogenicity of a vaccine candidate against Covid-19. 150 healthy volunteers will be enrolled and receive two shots of the vaccine candidate. All participants who receive two doses of the vaccine candidate will be invited to participate in the Booster phase.

NCT ID: NCT04670328 Completed - Covid19 Clinical Trials

Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity

Start date: May 1, 2020
Phase:
Study type: Observational

The hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.